| Literature DB >> 34336899 |
Alexandra Gruber-Wackernagel1, Tanja Schug1, Thomas Graier1, Franz J Legat1, Hanna Rinner1, Angelika Hofer1, Franz Quehenberger2, Peter Wolf1.
Abstract
Background: Little is known about the long-term course of polymorphic light eruption (PLE). Objective: To predict disease course, a questionnaire was sent to patients whose PLE had been diagnosed between March 1990 and December 2018 and documented in the Austrian Cooperative Registry for Photodermatoses.Entities:
Keywords: disease course; persistence; polymorphic light eruption; predictive factors; remission
Year: 2021 PMID: 34336899 PMCID: PMC8323194 DOI: 10.3389/fmed.2021.694281
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Patient flow chart.
Patient characteristics.
| Number/total number of patients (%) | 79/97 (81.4%) | 18/97 (18.6%) | |
| Age at disease onset (years), median, mean (SD), range | 24.0 | 30.0 | 0.534 |
| Age in years at providing the standard questionnaire: median, mean (SD), range | 34.0 | 37.5 | 0.846 |
| Skin phototype, number (percentage) | I 4 (5%) | I 0 (0%) | 0.067 |
| Type of PLE, number (percentage) patients | Mac: 48 (63%) | Mac: 8 (53%) | 0.636 |
| Lesions occurring in spring, summer, fall, winter. Number (percentage) patients | Spring 35 (49%) | Spring 6 (50%) | 0.551 |
| Persistence of skin lesions, hours (≤24 h), days (>1d-≤7d), weeks (>7d) | Hours: 19 (26%) | Hours: 1 (8%) | 0.113 |
| Occurrence of skin lesions within hours (≤24 h), days (>24 h) | Hours: 47 (69%) | Hours: 10 (91%) | 0.169 |
Mac, macular; Ves, vesicular; Pap, papular; Urt/plaq urticarial/plaques.; Na, no answer. P-values were determined by student's t-test and chi-square, or Fisher's exact test, whatever was the most appropriate.
Figure 2Course of disease in individual PLE patients. Blue and green represent individual patients and their time span from onset of disease to normalization of sun sensitivity (i.e., cessation of PLE symptoms) (green), being considered as event, or the end of the follow-up (not-normalized, blue), being considered as censored. N = 97 patients; three women did not exactly report the start and/or cessation or improvement of symptoms, and one man did not answer the question on the course of the disease at all, and thus the data for these four patients were not plotted.
Body site involvement in PLE.
| Face | 25 (32%) | 4 (22%) | 0.5714 |
| V-neck | 70 (90%) | 7 (39%) | |
| Neck | 24 (31%) | 6 (33%) | 0.9999 |
| Back | 19 (24%) | 8 (44%) | 0.1431 |
| Upper chest | 32 (41%) | 11 (61%) | 0.1878 |
| Abdomen | 21 (27%) | 5 (28%) | 0.9999 |
| Upper arm | 42 (54%) | 7 (39%) | 0.3017 |
| Forearm | 46 (59%) | 13 (72%) | 0.4217 |
| Thigh | 29 (37%) | 6 (33%) | 0.9999 |
| Lower leg | 32 (41%) | 7 (39%) | 0.9999 |
| Dorsum hand | 24 (31%) | 6 (33%) | 0.9999 |
| Dorsum feet | 22 (28%) | 5 (28%) | 0.9999 |
| na | 1 | 0 | na |
na, not available. P-values were determined by chi-square, or Fisher's exact test, whatever appropriate. Significant rates are printed in bold.
Course of PLE.
| Worse symptoms | 3 (4) | 30.0 | 0 (0) | |||
| Equal symptoms | 15 (19) | 32.0 | 7 (41) | 29.0 | ||
| Less symptoms | 29 (37) | 26.5 | 6 (35) | 30.0 | ||
| Normalized | 32 (41) | 15.5 | 28.0 [11.5] | 4 (24) | 8.0 | 23.5 [14.5] |
| All courses | 79 (100) | 28.0 | 17 (100) | 29.0 | ||
| na | 0 | 1 | ||||
Numbers in square brackets indicate time of follow up after cessation of disease. na, no answer available. One man did not answer the question on the course of the disease, and two women did not report the start; one woman did not report the time of cessation of symptoms, and thus the data for these four patients could not be included in the analysis of the follow-up and disease duration (see also footnote in .
Figure 3Kaplan-Meier analysis of persistence of PLE. Log-rank p-values are blotted in the individual graphs for (A) all patients and comparing (B) male vs. female gender (hazard ratio 1.75; 95%CI, 0.62–4.97), (C) skin phototype III/IV vs. I/II (1.29; 0.64–2.61), (D) PLE lesions during all seasons vs. spring/and or summer (0.92; 0.38–2.26), (E) occurrence of lesions after 24 h vs. within 24 h (0.86; 0.38–1.96), and (F) lesion persistence of more than 1 week vs. up to 1 week (2.47; 0.75–8.13).